

MAY 21 2003
PATENT & TRADEMARK OFFICE

AMENDMENT TO THE CLAIMS

1. (currently amended) An isolated peptide selected from the group consisting of comprising:

(X1)_n EVEKIKTTVKESATEEKLTPVX2L(X23)_m (SEQ ID NO: 1),

(Y1)_n EVAALQVDRKVADEEKQSYDAV(Y2)_m (SEQ ID NO: 2),

wherein

~~n and m independently represents 0 or 1;~~

~~X1, X2 and X3 are independently defined as follows~~

X1 is ~~GVKETPQQKYQRLLHEVQELTT (SEQ ID NO: 3), or~~

~~VKETPQQKYQRLLHEVQELTT (SEQ ID NO: 4), or~~

~~KETPQQKYQRLLHEVQELTT (SEQ ID NO: 5), or~~

~~ETPQQKYQRLLHEVQELTT (SEQ ID NO: 6), or~~

~~TPQQKYQRLLHEVQELTT (SEQ ID NO: 7), or~~

~~PQQKYQRLLHEVQELTT (SEQ ID NO: 8), or~~

~~QQKYQRLLHEVQELTT (SEQ ID NO: 9), or~~

~~QKYQRLLHEVQELTT (SEQ ID NO: 10), or~~

~~KYQRLLHEVQELTT (SEQ ID NO: 11), or~~

~~YQRLLHEVQELTT (SEQ ID NO: 12), or~~

~~QRLLHEVQELTT (SEQ ID NO: 13), or~~

~~RLLHEVQELTT (SEQ ID NO: 14), or~~

~~LLHEVQELTT (SEQ ID NO: 15), or~~

~~LHEVQELTT (SEQ ID NO: 16), or~~

~~HEVQELTT (SEQ ID NO: 17), or~~

~~EVQELTT (SEQ ID NO: 18), or~~

~~VQELTT (SEQ ID NO: 19), or~~

~~QELTT (SEQ ID NO: 20), or~~

~~ELTT (SEQ ID NO: 21), or~~

~~LT~~T, or

~~TT, or~~

~~T;~~

X2 is ~~V or L, and~~

X3 is ~~AKQLAAL (SEQ ID NO: 22), or~~

~~AKQLAA (SEQ ID NO: 23), or~~

RECEIVED

MAY 28 2003

TECH CENTER 1600/2900

~~AKQLA (SEQ ID NO: 24), or~~

~~AKQL (SEQ ID NO: 25), or~~

~~AKQ, or~~

~~AK, or~~

~~A;~~

and

~~Y1 and Y2 are independently defined as follows~~

~~Y1 is GEKETPVQKCQRLQIEMNELLN (SEQ ID NO: 26), or~~

~~EKETPVQKCQRLQIEMNELLN (SEQ ID NO: 27), or~~

~~KETPVQKCQRLQIEMNELLN (SEQ ID NO: 28), or~~

~~ETPVQKCQRLQIEMNELLN (SEQ ID NO: 29), or~~

~~TPVQKCQRLQIEMNELLN (SEQ ID NO: 30), or~~

~~PVQKCQRLQIEMNELLN (SEQ ID NO: 31), or~~

~~VQKCQRLQIEMNELLN (SEQ ID NO: 32), or~~

~~QKCQRLQIEMNELLN (SEQ ID NO: 33), or~~

~~KCQRLQIEMNELLN (SEQ ID NO: 34), or~~

~~CQRLQIEMNELLN (SEQ ID NO: 35), or~~

~~QRLQIEMNELLN (SEQ ID NO: 36), or~~

~~RLQIENINELLN (SEQ ID NO: 37), or~~

~~LQIEMNELLN (SEQ ID NO: 38), or~~

~~QIEMNIELLN (SEQ ID NO: 39), or~~

~~IENINELLN (SEQ ID NO: 40), or~~

~~EMNELLN (SEQ ID NO: 41), or~~

~~MNELLN (SEQ ID NO: 42), or~~

~~NELLN (SEQ ID NO: 43), or~~

~~ELLN (SEQ ID NO: 44), or~~

~~LLN, or~~

~~LN, or~~

~~N; and~~

~~Y2 is VATVISTAR (SEQ ID NO: 45), or~~

~~VATVISTA (SEQ ID NO: 46), or~~

~~VATVIST (SEQ ID NO: 47), or~~

~~VATVIS (SEQ ID NO: 48), or~~

~~VATVI (SEQ ID NO: 49), or~~

~~VATV (SEQ ID NO: 50), or~~

~~VAT, or~~

~~VA, or~~

~~V, and~~

derivatives a fragment thereof or a derivative thereof having at least about 90% identity with SEQ ID NO: 1 or SEQ ID NO: 2.

2. (original) The peptide of claim 1 which is

GVKETPQQKYQRLLHEVQELTTEVEKIKTTVKESATEEKLTPVX2LAKQLAAL
(SEQ ID NO: 51),

wherein X2 is as defined in claim 1.

3. (original) The peptide of claim 1 which is

GEKETPVQKCQRLQIEMNELLNEVAALQVDRKVADEEKQSYDAVVATVISTAR (SEQ
ID NO: 52).

4-8. (canceled)

9. (original) The peptide of claim 1 capable of modulating cellular proliferation.

10. (original) The peptide of claim 1 capable of inhibiting cellular proliferation.

11. (original) The peptide of claim 10 capable of selective inhibition of cancerous cells.

12-14. (canceled)

15. (original) A composition comprising a peptide of claim 1 in admixture with a pharmaceutically acceptable carrier.

16. (canceled)

17. (original) A method for inhibiting cellular proliferation comprising delivering to a target cell an effective amount of an isolated peptide of claim 1 or a nucleic acid encoding said peptide.

18-20 (canceled)

EI 21. (original) The method of claim 17 wherein said target cell is a tumor cell.

22. (original) The method of claim 21 wherein said tumor cell is a cancer cell.

23-27. (canceled)
